Some diseases, such as arthritis and rheumatoid arthritis, may be associated with excessive accumulation or abnormal activation of CS. Therefore, by developing inhibitors of CS, it is possible to intervene in its role in disease development in a targeted manner, thereby helping to control disease progression and alleviate associated symptoms. CD BioGlyco offers inhibitor development services targeting CS biosynthesis processes, thereby inhibiting the synthesis of CS. The inhibitor development services we offer include but are not limited to the following directions:
Fig.1 Process of CS inhibitor development. (CD BioGlyco)
Fig.2 Conventional scheme for CS biosynthetic machineries. (Mikami & Kitagawa, 2011)
CD BioGlyco provides comprehensive solutions for Glycosylation Inhibitor Development, which include our CS Inhibitor development service. We provide expert-designed experimental plans to deliver professional, high-quality support for your scientific projects in line with our broad vision. For more information, please feel free to contact us.